ClinicalTrials.gg

Program

TOLLB-001

A development code. Also written as “TollB-001 tablets”, “TollB-001” and “TollB-001 Tablet”.

Its studies are mostly in Arthritis, Rheumatoid · Scleroderma, Systemic, led by Toll Biotech Co. Ltd. (Beijing).

Furthest: phase 2, since Jan 29, 20263 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Toll Biotech Co. Ltd. (Beijing)32 open or runningphase 2since Jan 29, 2026Sep 22, 2023Dec 2026phase 2 · NCT07408024

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 22, 2023First study: phase 1 study in Arthritis, RheumatoidFirst studyNCT06103773 · 98 enrolled · China
  2. Jan 29, 2026Phase 2 study in Arthritis, RheumatoidPhase 2 reachedNCT07408024 · 24 planned · China
  3. Jul 28, 2026Phase 2 study in Scleroderma, SystemicNCT07745725 · 36 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in Arthritis, RheumatoidNCT07408024
  2. Oct 2027Primary completion: phase 2 study in Scleroderma, SystemicNCT07745725

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07745725Scleroderma, Systemic · China2Not yet recruitingOct 202736
NCT07408024Arthritis, Rheumatoid · China2RecruitingDec 202624
NCT06103773Arthritis, Rheumatoid · China1CompletedApr 7, 202598

How it is read

Names in the registry

  • “TollB-001 tablets”, 1 entry
  • “TollB-001”, 1 entry
  • “TollB-001 Tablet”, 1 entry

Codes read as this program: TOLLB001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.